European Leukemia Trial Registry

More Details
Title Darbepoetin Alfa in Anemic Low or Intermediate-1 Risk MDS
Scientific Title A Multicenter, Randomised, Double-blind, Placebo-controlled Study of Darbepoetin Alfa for the Treatment of Anaemic Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Short Title ARCADE
Trialgroup Deutsche MDS
Type of Trial multicentric, randomized, double-blind
Disease Myelodysplastic Syndrome(MDS) Low risk and intermedia I
Age >= 18 years
Status Closed
Start of Recruitment 01.02.2013
Leader Platzbecker, Prof. Dr. med., Uwe
Shortprotocol Shortprotocol
created 04.02.2013 Sina Hehn
changed 30.11.2016 Eva-Maria Ableidinger
ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | |